登录 |  注册 |  忘记密码 |  购卡 |  公司首页
简体   繁體   English
首页 > 中华医学杂志(英文版) >Treatment of patients with severe sepsis using Ulinastatin and Thymosin α1: a prospective, randomized, controlled pilot study

Treatment of patients with severe sepsis using Ulinastatin and Thymosin α1: a prospective, randomized, controlled pilot study

    加入收藏夹      点击:84     下载:1     被引:10

Background Tradition treatment of sepsis and new therapies, including high dose corticosteroids and non-steroidal anti-inflammatory drugs, have proven unsuccessful in improving survival. This study aimed to evaluate the potential efficacy of immunomodulating therapy using Ulinastatin (UTI) plus Thymosin α1 (Tα1) for improving organ function and reducing mortality in patients with severe sepsis.Methods A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard. All patients had severe sepsis and received standard supportive care and antimicrobial therapy. Fifty-nine patients were also administered UTI plus Tα1 (defined as Group A), 55 patients were given a placebo (defined as Group B). Clinical parameters were determined by evaluation with the Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ), multiple organ failure (MOF) and the Glasgow Coma Scores (GCS) on entry and after therapy on the 3rd, 8th, and 28th day. By flow cytometery and ELISA lymphocyte subsets and cytokines were analyzed. Survival analysis was determined by the Kaplan-Meier method at 28, 60, and 90 days. Results Based on comparison of the two groups, patients in Group A exhibited a better performance in organ failure scores which was noticeable soon after initiation of treatment. Patients in Group A also demonstrated a better resolution of pre-existing organ failures during the observation period. After initiation of treatment, significant improvements in the CD4+/CD8+ ratio, a quicker balance between proinflammatory mediators such as tumor necrosis factor a, interleukin 6 and anti-inflammatory cytokines including interleukin 4 and interleukin 10 were found. This was followed by cumulative survival increases of 17.3% at 28 days, 28.9% at 60 days, and 31.4% at 90 days in Group A. The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy.Conclusion UTI plus Tα1 has a beneficial role in the treatment of severe sepsis.

作 者 CHEN Hao;HE Ming-yan;LI Yu-min
刊 名 中华医学杂志(英文版)  2009年122卷08期 883-888页  科学引文索引(Science Citation Index)收录科学引文索引扩展版(SCI Expanded)收录美国国立医学图书馆Medline数据库收录美国生物学预评数据库(BIOSIS Previews)收录美国《化学文摘》(Chemical Abstracts)收录中国科技论文统计源期刊(中国科技核心期刊)收录
英文期刊名 CHINESE MEDICAL JOURNAL
关键词 Ulinastatin Thymosinal severe sepsis immunomodulatory therapy
分类号 R5
DOI号 10.3760/cma.j.issn.0366-6999.2009.08.001

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他相关网站。

北京万方数据股份有限公司

万方数据电子出版社

关于我们  |   联系我们  |   网站地图  |   主要产品  |   主要服务

使用帮助  |   服务承诺  |   诚聘英才  |   友情链接  |   知识产权

客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

客服邮箱:yiyao@wanfangdata.com.cn

充值卡购卡热线:400-667-1808

互联网出版许可证 新出网证(京)字042号

互联网药品信息服务资格证书号:(京)-经营性-2011-0017

信息网络传播视听节目许可证

北京市公安局海淀分局备案号:110109081585

京ICP证010071号